US-based genomic sequencing amplification technology developer BioSkryb has collected $11.5m in a seed round featuring law firm Wilson Sonsini Goodrich & Rosati that was led by venture capital firm Anzu Partners.
Founded in 2018 on the back of Stanford University research, Bioskryb is developing technologies that amplify existing genetic sequencing systems so researchers can model near-complete genomes of the DNA in single cells using limited samples.
The company’s technology is principally tailored to cancer single-cell genomics and bacterial genomics. It builds on research by Charles Gawad, a clinical instructor in the haematology and oncology branch of Stanford’s paediatric unit.
The funding will go to product development in the translational research and clinical diagnostics spaces, centred around both genomic and transcriptomic applications, with the latter encompassing studies of whole RNA structures.